


PHARM TECH CONFERENCE

'82

PART 1



Pharm Tech Conference '82

**SHERATON CENTRE HOTEL
NEW YORK CITY**

SEPTEMBER 21-23, 1982

Copyright © 1982 by Pharmaceutical Technology Corporation.

All rights reserved. No part of this book may be reproduced or used in any form or by any means — graphic, electronic, or mechanical, including photocopying, recording, taping, or information storage and retrieval systems — without written permission of the publisher.

Printed in the United States of America
10 9 8 7 6 5 4 3 2 1

Library of Congress Catalog Card Number: 82-61410
ISBN: 0-943330-01-7

Published by Pharmaceutical Technology Publications
320 North A Street, P.O. Box 50, Springfield, Oregon 97477
(503) 726-1200

Pharm Tech Conference '82

New York City

Edward D. Aster, Publisher

Marilou B. Sturges, Editorial & Conference Director

James McCloskey, Editor, Pharmaceutical Technology

Linda S. Pierce, Conference Assistant

Mary Jean Kelso, Editorial Secretary

W.G. von Torne Jr., Production Director & Cover Art

Ravitej Khalsa, Production Coordinator

Karen Carlson, Production Editor

Marlene G. Weir, Graphic Design Coordinator

About Pharm Tech Conference '82

Pharm Tech Conference, the premier international conference for the pharmaceutical industry, is produced annually by *Pharmaceutical Technology* magazine in conjunction with Interphex USA, the premier international exhibition for the industry.

Pharm Tech Conference '82 featured 128 speakers, panelists, and chairmen, drawn from 56 major pharmaceutical firms, 10 colleges of pharmacy, 5 law firms, the Food and Drug Administration, the Pharmaceutical Manufacturers Association, and the Health Industry Manufacturers Association. More than 1500 of the world's foremost pharmaceutical manufacturers, researchers, academicians, and regulators attended Pharm Tech Conference '82, representing the total spectrum of pharmaceutical manufacturing.

This official proceedings includes the texts of 77 papers presented at the conference and is a unique reference source for the state-of-the-art in pharmaceutical research, manufacturing, and regulation. The papers published within this volume emphasize the analysis of new technologies and methods for production, quality control, packaging, and

research and development as well as the rules and regulations governing their use.

Pharm Tech Conference '82 represents the efforts not only of the staff of *Pharmaceutical Technology* but the efforts of many within the industry itself. *Pharmaceutical Technology* is particularly indebted to its conference chairmen, whose guidance has provided the strength and scope that characterize these proceedings:

G. Marshall Abbey
Vice President,
Secretary & General Counsel,
Baxter Travenol Laboratories, Inc.
Michael J. Akers, PhD
Research Scientist,
Parenterals Development,
Eli Lilly & Co.
Gilbert S. Banker, PhD
Professor & Head,
Dept. of Industrial &
Physical Pharmacy,
Purdue University
Joseph F. Bavitz
Research Fellow,
Merck Sharp & Dohme
Research Laboratories
Peter Bernardo, PhD
Head of Pharmaceutical Development,
Medical Research Div.,
American Cyanamid Co.
George Burditt
Partner,
Burditt & Calkins
Dale Fonner, PhD
Manager of Pharmaceutical Production
Technical Support, The Upjohn Co.
Daniel Harpaz, PhD
Director of Technical Services,
Revlon Health Care Group
James Harris, PhD
Director of Sterile Operations,
Merck Sharp & Dohme
Walter W. Holl, PhD
Senior Investigator,

Analytical & Physical Chemistry,
Smith Kline & French Laboratories
Howard M. Holstein
Vice President & General Counsel,
Health Industry Manufacturers
Association
Diana Kolaitis
Supervisory Investigator,
Food and Drug Administration
Leon Lachman, PhD
President,
Lachman Consultant Services
Owen Lamb
Director, Corporate Quality Assurance,
Warner-Lambert Co.
Jerry A. Lott
Director of Package Design &
Development, Pfizer, Inc.
Thomas D. O'Connor
Manager, Performance Improvement,
Merck Sharp & Dohme
Kenneth C. Olson
Process Development, Genentech, Inc.
Gerald Papariello, PhD
Director of Pharmaceutical Research &
Development, Wyeth Laboratories
Edward D. Purich, PhD
Chief of Pharmacokinetics Branch,
Food and Drug Administration
Christopher T. Rhodes, PhD
Professor & Chairman,
Dept. of Pharmacy,
University of Rhode Island
Joseph B. Schwartz, PhD
Professor of Pharmaceutics,
Philadelphia College of Pharmacy
& Science
Alan J. Smith, PhD
Assistant Director,
Corporate Quality Assurance,
Ayerst Laboratories
Jon R. Wallace
Corporate GMP Compliance Supervisor,
U.S. Surgical Corp.
H.C. "Red" Welch
Manager, Packaging Development,
The Upjohn Co.
Thomas W. Wilkin
Manager,
Management Training,
Schering Plough Corp.
Paul Wray
Director of Pharmaceutical
Development, Ortho Pharmaceuticals

Table of Contents

Technical & Regulatory Aspects of Drug Manufacture Using Recombinant DNA

- Fermentation in the Application of Recombinant DNA Technology to the Production of Pharmaceuticals. **3**
S. Edward Lee, PhD, Research Group Chief, Fermentation Pilot Plant, Hoffmann-La Roche.
- Ultrafiltration Processes in Biotechnology. **6**
Robert S. Tutunjian, Director, Industrial Marketing, Amicon Corp., and Barry Breslau, PhD, Director of Process Research, Romicon Corp.
- FDA Regulation of Drug Products Manufactured by the Recombinant DNA Technique. Deborah Shur Trinker, Attorney, and Edward L. Korwek, PhD, Attorney, Keller and Heckman. **23**
- Recombinant DNA Technology in the Pharmaceutical Industry: A View of the Future. Burke K. Zimmerman, PhD, Research Planning, Cetus Corp. **35**
-

Quality Assurance & Control

- The Organization of Quality Control and Quality Assurance. Stephen M. Olin, PhD, Vice President, Quality Affairs, and Alan J. Smith, Assistant Director, Quality Assurance, Ayerst Laboratories. **41**
- The Quality Cost System. John E. Condon, DSc, Vice President, Corporate Quality Assurance, Abbott Laboratories. **43**
- A Procedural Approach to Quality Assurance. Kenneth G. Chapman, Director, Quality Assurance Audit, Quality Control Division, Pfizer, Inc. **45**
- A Systems Approach to Quality Assurance — Omnibus Management and Documentation System. Ted C. Fleming, Vice President, Corporate Quality Assurance, L.G. Hodgkins, Director, Corporate Quality Standards and Systems, and P.M. Clark, Documentation Analyst/Auditor, Alcon Laboratories, Inc. **61**
- Analyzing Quality Trends. Larry L. Simms, Industrial Engineer, Eli Lilly & Co. **77**

Validation

- Process Validation of a New Product. Carl B. Rifino, PhD, Supervisor, Process Development, Stuart Pharmaceuticals. 90
- Practical Considerations in Retrospective Validation. James P. Agalloco, Section Head, Pharmaceutical Engineering, Squibb Institute for Medical Research, E.R. Squibb & Sons, Inc. 101
- Using a Data Logging System for "Sterilize-in-Place" Validation. Leo O. Hura, Senior Quality Control Project Engineer, Process Validation Dept., Barry D. Garfinkle, PhD, Manager, Process Validation Dept., George J. Grigonis Jr., Associate Quality Control Engineer, Process Validation Dept., and Alan Gray, PhD, Director, Biologics, Merck Sharp & Dohme. 105
- The Use of Process Profiles in a Validation Program. Robert D. Goorsky, Validation Manager, and Jeannie Vawter, Manufacturing Technical Documents Coordinator, Alcon Laboratories, Inc. 117
- Revalidation: — How, When, Why? J. Patrick Jeater, Supervisor of Manufacturing Process Validation Group, and Leo F. Cullen, PhD, Associate Director, Pilot Plant Subdivision, Pharmaceutical Research & Development Division, Wyeth Laboratories. 126

Quality Control in Generic-Drug Formulation

- The Statistics of Bioequivalence Trials. Wilfred J. Westlake, PhD, Director, Clinical Data Management, Smith Kline & French Laboratories. 141
- Quality Assessment Through In Vitro & In Vivo Testing. Marvin C. Meyer, PhD, Professor & Vice Chairman, Dept. of Pharmaceutics, University of Tennessee Center for the Health Sciences. 149
- Quality Control in the Development Program of a Generic-Drug Manufacturer. Cheryl D. Blume, PhD, Technical Director, Mylan Pharmaceuticals, Inc. 158

The Quality System for Lederle Standard Products. 162
Stuart A. Rose, PhD, Director of Pharmaceutical Quality Control, Lederle Laboratories.

Translation of a Development Formulation to Routine Production: A Step-Wise Procedure. 168
Seymour Hyden, PhD, Vice President, Quality Assurance, Cord Laboratories, Inc.

Solid Dosage I

Relationship Between the Process of Manufacture and the Structure & Properties of Granules and Tablets. 175
Harry Seager, PhD, Technical Director, R.P. Scherer Ltd., United Kingdom.

Photomicrographic Analysis of Water Vapor Sorption & Swelling of Selected Super-Disintegrants. 211
R. Gary Hollenbeck, PhD, Asst. Professor of Pharmaceutics, and Ampol Mitrevej, Research Asst., Dept. of Pharmaceutics, School of Pharmacy, University of Maryland.

Induction of Plastic Behavior into a Particulate Mass by Addition of a Granulating Agent. 225
N. Anthony Armstrong, PhD, Senior Lecturer in Pharmaceutics, Welsh School of Pharmacy, Nadia M.A.H. Abourida, PhD, University of Wales, and Angela Gough, Welsh School of Pharmacy.

Water-Based Controlled-Release Drug Delivery Systems. 234
Isaac Ghebre-Sellassie, PhD, Research Associate, Gilbert S. Banker, PhD, Professor & Head, and Garnet Peck, PhD, Professor, Dept. of Industrial & Physical Pharmacy, Purdue University.

Medical Device Regulation I

Development of the Medical Amendments of 1976. 244
Stephan E. Lawton, Attorney, Pierson, Ball & Dowd, and former Chief Counsel for the Subcommittee on Health & Environment, U.S. House of Representatives.

Implementation of Regulations from an Industry Perspective. 248
Rodney R. Munsey, Attorney, Dickstein, Shapiro & Morin.

• Comparison of the Drug and Device Approval Process. Robert G. Britain, Acting Associate Director for Device Evaluation, Bureau of Medical Devices, FDA.	264
An Overview & Prospective Look at FDA Regulations. Robert S. Kennedy, PhD, Vice President, Research & Development, American Optical Scientific Instruments Group.	269
New Product Approvals & the Use of Advisory Committees. Marc H. Bozeman, Partner, Geller & Bozeman.	273

Laboratory Instrumentation: Automation & Computer Applications

The Instrumentation of Tablet & Capsule Filling Machines. Keith Marshall, PhD, Director, The Institute for Applied Pharmaceutical Sciences, The Center for Professional Advancement.	284
An Overview of Modern Instrumentation Needs for the Pharmaceutical Industry. David J. Fraade, Head, Automation & Control Group, Burroughs Wellcome Co., Greenville, NC.	299
Approaching Laboratory Automation & Data Management — One Q.C. Lab's Experience. Peter G. Berthrong, Lead Analyst, Analytical Control Laboratory, and Bruce C. Schaeffer, Scientific Analyst/Programmer, Smith Kline & French Laboratories.	311
Computer Applications in the Pharmaceutical Analysis Laboratory. Eugene McGonigle, PhD, Section Head, Pharmaceutical Analysis, Ortho Pharmaceutical Corp.	323
The Automation of Particulate Inspection for Parenteral Products. Julius Z. Knapp, Director, R & D Engineering, Schering Corp.	336
Automated Dissolution Testing of Sustained Release Tablets. Thomas S. Pattison, Senior Chemist, and Rebecca J. Allen, PhD, Manager, Analytical Research Group, Shaklee Corp.	352

GMP Training

- From the Ground Up: Sterile-Technique Training in a New Facility.** Lynn D. Starkman, Trainer, Performance Improvement, Merck Sharp & Dohme. **369**
- "Why Government Regulation?" — A Fresh Approach to GMP Training.** Elaine Lehecka, Supervisor, Manufacturing Training, Schering Corp. **372**
- Internal Production of Slide/Tape Training Programs.** Patricia P. Russell, Manager of Training and Development, Astra Pharmaceutical Products, Inc. **375**
- Developing an In-House Training Aid: A Case Study.** Thomas Becze, Director of Regulatory Training & Compliance, Pharmaceutical Technology, Inc. **386**
- A Unique Training Concept for Pharmaceutical Manufacturers.** Craig Stewart, President, Craig Stewart & Associates. **390**
- Establishing a GMP Newsletter.** Janet J. Lieberman, PhD, Supervisor of Training, Wyeth Laboratories, Inc. **395**
-

Solid Dosage II

- Recent Research on Methods for Improving Dissolution Rates from Solid Oral Dosage Forms.** James W. McGinity, PhD, Associate Professor & Assistant Director, and Rodney Pearlman, PhD, Asst. Professor of Pharmaceutics, Drug Dynamics Institute, College of Pharmacy, The University of Texas at Austin. **400**
- Formulation of Sustained-Release Matrix Systems with Cellulose Ether Polymers.** Daniel A. Alderman, Senior Research Engineer, Designed Products Dept., The Dow Chemical Co. **409**
- An Improved Method to Evaluate the Mechanical Strength of Tablets.** Gerald Gold, PhD, Head, Exploratory Research Section, Applied Pharmaceutics Laboratory, Pharmacy Research Dept.; Harish B. Pandya, Associate Research Scientist, Pharmacy Research Dept.; Ronald N. Duvall, PhD, Director, Applied Pharmaceutics Laboratory, Pharmacy Research Dept.; Blaze T. Palermo, Director of Pharmaceutical Research & Development, Consumer Health Care Division, Miles Laboratories, Inc. **424**

An Evaluation of Alternate Sources of Directly Compressible Tablet Excipients & Acetaminophen. Larry G. Miller, PhD, Director, Pharmacy Research Product Development Dept., Manoj N. Shah, PhD, Senior Research Pharmacist, and Myra A. Carroll, Pharmacist, A.H. Robins Co. 439

Determination of Stability of Release Rates for Sustained-Release Dosage Forms. Sanford Bolton, PhD, Associate Professor, College of Pharmacy & Allied Health Professions, St. John's University. 451

Medical Device Regulation II

New Product Development — A Measurable Process. Ernest A. Carabillo Jr., Asst. Professor of Pharmaceutical Sciences, St. John's University College of Pharmacy & Allied Health Professions. 467

Medical Device Labeling: A Compliance Program. Max Sherman, Director, Regulatory Affairs, Zimmer, Inc. 475

Documenting the Quality Program (With Less Paper). Victor J. Goetz, Manager, Quality Engineering, Corporate Productivity Dept., Warner-Lambert Co. 484

An Overview of Investigational Device Exemption. Arnold I. Friede, Counsel to Baker Instruments Corp., J.T. Baker Chemical Co., Vicks Toiletries Div., Richardson Vicks Co. 487

Premarket Notification — 510(K) Submissions. Michael B. McCulley, General Attorney, Johnson & Johnson. 488

Process Automation

Process Control with Computer Automation. Chuck E. Willis, Technical Services Manager, Sterling Drug, Inc., McPherson, Kansas. 496

A Minicomputer Application for Off-Line Pharmaceutical Weighing Operations. Mark Rosenbaum, Production Supervisor, John Maddox, Production Manager, Mary Hirschberg, Manager, Manufacturing & Quality Assurance Systems Development Dept., and Alan Bailey, Systems Analyst, Manufacturing & Quality Assurance Systems Development Dept., Mead Johnson & Co. 505

MSDI's Computerized Manufacturing Facility. Ronald L. Corbin, Operations Engineer, Manufacturing Services Dept., International Division, Merck Sharp & Dohme.	516
An Automated Granulating Process. Anthony J. Behe, Manufacturing Supervisor, Tablet Manufacturing Dept., William H. Rorer, Inc.	521
Direct Digital Control Applied to a Batch and Continuous Pharmaceutical Process. Lon Casebolt, Project Engineer, Ohio Medical Anesthetics, and Robert E. Sirany, Industry Marketing Manager, Rosemount, Inc.	525
SYNLIB — A Graphics Approach to Reaction Retrieval. Daniel F. Chodosh, PhD, Manager, Automated Chemical Technology, and Wilford L. Mendelson, Smith Kline & French Laboratories.	533

Parenterals

The Theory and Practice of Radiation Technology — A Summary as it Applies to Parenterals. Martin A. Welt, PhD, President, Radiation Technology, Inc.	540
Computer Process Control of Sterile Pharmaceutical Manufacturing. Charles A. Baechler, PhD, Applications Development Engineer, Corporate Division of Automation & Control, Merck & Co., Inc.; and Lee F. Schuchardt, PhD, Senior Project Microbiologist, Biological Production Technical Services Dept., Merck Sharp & Dohme.	561
Developments in Compendial Standards for Sterility Tests and their Relation to Sterility Assurance in Manufacturing Control. Aubrey S. Outschoorn, PhD, Senior Scientist, Drug Standards Division, USP.	570
Investigations on Glass Delamination with Parenteral Solutions. R.V. Kasubick, PhD, Group Manager, Elio P. Mariani, PhD, Asst. Director, and Edward C. Shinal, PhD, Director, Product Development Research, Science & Technology Div./Pharmaceutical R&D Div., Bristol-Myers Co.	577
Basic Concepts on Airborne Particles in Drug and Medical Device Manufacturing Environments. Dan R. Choman, PhD, Manager, Scientific & Manufacturing Compliance, Lederle Laboratories.	588

A Dedicated Computer Control System for Lyophilizer Operations. David J. Fraade, Head, Automation & Control Group, and Fred Riggs, Systems Engineer, Automation Engineering Group, Burroughs Wellcome Co., Greenville, NC.	600
--	-----

The FDA Field Inspection

Planning Inspections of Drug Firms in a District Office. Paula J. Oliver, Director, Investigations Branch, Philadelphia District, FDA.	615
Conduct of a Drug GMP Inspection. Henry L. Avallone, Field Investigator & Drug Specialist, Edison Resident Post, Newark District, FDA.	621
The Scope and Purpose of "Other" FDA Inspections at Pharmaceutical Manufacturers. Peter D. Smith, Investigator, Bridgeport Office, FDA.	626
From Inspection to Legal Action. Anthony Panzica, Compliance Officer, Newark District, FDA.	633
Recalls — What Does FDA Require? Marc M. Feinberg, Recall & Emergency Coordinator, Philadelphia District, FDA.	638

Regulatory Affairs

The OTC Drug Review — What's Happening Now. William E. Gilbertson, Director, Division of OTC Drug Evaluation, Bureau of Drugs, FDA.	644
IND/NDA Regulatory Revisions — Possible Pitfalls in Practical Applications. Lewis M. Horger, PhD, Vice President, Regulatory Affairs, U.S. Pharmaceutical Products, Smith Kline & French Laboratories.	645
Paper NDA: Step II in the Revolution of Generic-Drug Approvals. Robert H. Becker, Partner, Kleinfeld, Kaplan and Becker.	649
Pharmaceutical Look-Alikes — Competition & Consumer Choice. Bruce J. Brennan, Vice President & General Counsel, Pharmaceutical Manufacturers Association.	656
A New Approach to Antibiotics: New Issues to Ponder. Eugene M. Pfeifer, Attorney, Burditt & Calkins.	663

Packaging

- Ionizing Radiation for Sterilization of Medical & Pharmaceutical Products.** T. Downes, PhD, Asst. Professor, School of Packaging, Michigan State University. **666**
- A Preliminary Procedure for Screening Elastomeric Closures.** Thomas L. Grimes, PhD, Senior Research Scientist, The Upjohn Co. **675**
- Improved Barrier Materials for Solid & Liquid Unit of Use Packaging.** Arthur A. Hirsch, PhD, Technical Director, and Stan Manne, Vice President & General Manager, Lamcote Div., Arvey Corp. **685**
- Packaging Pharmaceutical Products in Plastic Bottles.** James A. Strassenburgh, General Manager, Wheaton Plastics of Puerto Rico. **692**
- Pharmaceutical Aerosol Technology — An Update.** Harvey Mintzer, General Manager, Armstrong Laboratories. **699**

Unpublished Presentations

- Technical & Regulatory Aspects of Drug Manufacture Using Recombinant DNA: Practical Aspects of the Recovery of Proteins Produced by Recombinant DNA Technology.** Joseph Tarnowski, PhD, Research Group Chief, Biopolymer Dept., Central Research Div., Hoffmann-LaRoche.
- Quality Control in Generic-Drug Formulation: What are the Standards for Bioequivalency?** William H. Barr, PhD, Professor & Chairman, Dept. of Pharmacy & Pharmaceuticals, Medical College of Virginia, Virginia Commonwealth University.

Technical & Regulatory Aspects of Drug Manufacture Using Recombinant DNA

**Chairmen: Kenneth C. Olson, Process Development,
Genentech, Inc., and Christopher T. Rhodes, PhD,
Professor & Chairman, Dept. of Pharmacy, University
of Rhode Island.**

**Fermentation in the Application of Recombinant
DNA Technology to the Production of Pharmaceuticals**

S. Edward Lee
Research Section Chief, Bioengineering Section
Chemical Research Department
Hoffmann-La Roche Inc.
Nutley, New Jersey 07110

Fermentation is an ancient technology. Its evolution encompasses six periods, each contributing different products for the well-being of human beings.

1. Prehistorical: Alcoholic drinks and aged/preserved meat
2. Pre-Pasteur: Cheese, yogurt, sour milk, bread, beer and soy sauce. It was not until 1857 that Pasteur proved that fermentation was brought about by living microorganisms.
3. Pre-WW I (1857-1914): Production of bakers' yeast in deep aerated tanks
4. WW I to WW II (1914-1939): Acetone, butanol, citric acid and other organic acids
5. Post-WW II (1939-1973): Antibiotics, vitamins, steroids, enzymes and amino acids
6. rDNA (1973-): Insulin, growth hormones, interferons and vaccines.

Genetic information is stored in living cells in the double helix of DNA. Each "structural gene" encodes a specific protein. There are several thousand structural genes in a bacterium. The encoding or the "expression" of a structural gene into a protein involves the following processes:

1. Transcription of DNA into mRNA,
 - A promoter region where RNA polymerases bind to the DNA
 - An initiation region for initiation of mRNA formation
 - An operator region for regulatory controls, and
 - A termination region for termination of DNA transcription.
2. Translation of mRNA on ribosomes into protein
 - A ribosome binding site where ribosomes bind to the mRNA
 - A start codon for initiation of protein synthesis, and
 - A stop codon for termination of mRNA translation.

Recombinant DNA technology makes possible the production of any protein, such as human protein, by a microorganism through the introduction of the gene which codes for that protein into the "host" microorganism.

Recombinant DNA technology is expected to have major economic and social impacts in the production of pharmaceuticals. Some estimates put